Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 52 | 2023 | 162 | 14.760 |
Why?
|
Anti-Asthmatic Agents | 17 | 2023 | 34 | 5.120 |
Why?
|
Hypersensitivity | 7 | 2023 | 48 | 2.700 |
Why?
|
Adrenal Cortex Hormones | 13 | 2023 | 117 | 2.610 |
Why?
|
Physicians | 6 | 2022 | 123 | 2.600 |
Why?
|
Telemedicine | 7 | 2023 | 119 | 2.460 |
Why?
|
Medication Adherence | 12 | 2023 | 81 | 2.310 |
Why?
|
Patient Education as Topic | 9 | 2021 | 160 | 2.290 |
Why?
|
Burnout, Professional | 4 | 2022 | 41 | 2.270 |
Why?
|
Coronavirus Infections | 7 | 2020 | 90 | 1.970 |
Why?
|
Pneumonia, Viral | 7 | 2020 | 94 | 1.960 |
Why?
|
Child | 29 | 2023 | 1423 | 1.560 |
Why?
|
Humans | 79 | 2023 | 28560 | 1.500 |
Why?
|
Community Health Workers | 7 | 2022 | 35 | 1.400 |
Why?
|
Administration, Inhalation | 14 | 2022 | 45 | 1.320 |
Why?
|
Adolescent | 24 | 2023 | 2319 | 1.160 |
Why?
|
Pandemics | 11 | 2022 | 260 | 1.080 |
Why?
|
Behavior Therapy | 2 | 2017 | 92 | 0.990 |
Why?
|
Caregivers | 7 | 2019 | 203 | 0.940 |
Why?
|
Nebulizers and Vaporizers | 8 | 2022 | 25 | 0.910 |
Why?
|
Mobile Applications | 2 | 2020 | 32 | 0.820 |
Why?
|
Betacoronavirus | 5 | 2020 | 77 | 0.800 |
Why?
|
Emergency Service, Hospital | 8 | 2020 | 259 | 0.780 |
Why?
|
Biological Products | 1 | 2022 | 45 | 0.740 |
Why?
|
Environmental Exposure | 2 | 2018 | 17 | 0.700 |
Why?
|
Allergy and Immunology | 4 | 2020 | 5 | 0.700 |
Why?
|
Monitoring, Ambulatory | 1 | 2020 | 19 | 0.690 |
Why?
|
Poverty | 3 | 2020 | 100 | 0.670 |
Why?
|
Surveys and Questionnaires | 8 | 2022 | 1220 | 0.640 |
Why?
|
Adult | 20 | 2023 | 8168 | 0.630 |
Why?
|
Parents | 2 | 2018 | 126 | 0.610 |
Why?
|
Emigrants and Immigrants | 2 | 2018 | 24 | 0.610 |
Why?
|
Respiratory Tract Diseases | 1 | 2018 | 7 | 0.600 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 43 | 0.600 |
Why?
|
Health Literacy | 4 | 2021 | 109 | 0.580 |
Why?
|
Registries | 1 | 2019 | 188 | 0.580 |
Why?
|
Female | 31 | 2023 | 15818 | 0.580 |
Why?
|
Male | 30 | 2023 | 15400 | 0.560 |
Why?
|
Self Care | 5 | 2020 | 105 | 0.560 |
Why?
|
Decision Making | 1 | 2018 | 229 | 0.520 |
Why?
|
Assertiveness | 1 | 2015 | 8 | 0.510 |
Why?
|
Child, Preschool | 8 | 2022 | 690 | 0.510 |
Why?
|
Urban Population | 5 | 2013 | 158 | 0.470 |
Why?
|
Chicago | 7 | 2019 | 939 | 0.450 |
Why?
|
United States | 9 | 2023 | 2197 | 0.430 |
Why?
|
Social Support | 2 | 2021 | 215 | 0.430 |
Why?
|
Family | 3 | 2021 | 115 | 0.420 |
Why?
|
Bronchodilator Agents | 3 | 2022 | 21 | 0.420 |
Why?
|
Immunization, Passive | 5 | 2023 | 14 | 0.410 |
Why?
|
Patient Compliance | 2 | 2011 | 164 | 0.410 |
Why?
|
MP3-Player | 2 | 2013 | 5 | 0.410 |
Why?
|
Minority Groups | 4 | 2019 | 87 | 0.400 |
Why?
|
House Calls | 3 | 2021 | 22 | 0.380 |
Why?
|
Electronics | 2 | 2021 | 11 | 0.370 |
Why?
|
Fellowships and Scholarships | 2 | 2022 | 44 | 0.360 |
Why?
|
Health Services Accessibility | 2 | 2023 | 110 | 0.360 |
Why?
|
Computer Security | 2 | 2020 | 6 | 0.350 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2020 | 18 | 0.350 |
Why?
|
Socioeconomic Factors | 5 | 2021 | 308 | 0.340 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2011 | 185 | 0.340 |
Why?
|
Stress Disorders, Post-Traumatic | 4 | 2021 | 235 | 0.330 |
Why?
|
Asthma, Exercise-Induced | 1 | 2009 | 1 | 0.320 |
Why?
|
Hospitalization | 3 | 2022 | 322 | 0.320 |
Why?
|
Adrenergic beta-Agonists | 1 | 2009 | 16 | 0.320 |
Why?
|
Athletes | 1 | 2009 | 89 | 0.290 |
Why?
|
Communication Barriers | 1 | 2007 | 4 | 0.290 |
Why?
|
Adaptation, Psychological | 2 | 2020 | 183 | 0.290 |
Why?
|
Language | 1 | 2007 | 71 | 0.280 |
Why?
|
Quality Improvement | 3 | 2018 | 161 | 0.280 |
Why?
|
Research Design | 2 | 2019 | 208 | 0.270 |
Why?
|
Electronic Health Records | 3 | 2020 | 75 | 0.240 |
Why?
|
Severity of Illness Index | 5 | 2021 | 990 | 0.230 |
Why?
|
Monitoring, Physiologic | 2 | 2022 | 76 | 0.220 |
Why?
|
Albuterol | 4 | 2022 | 19 | 0.220 |
Why?
|
Urticaria | 1 | 2023 | 4 | 0.220 |
Why?
|
Transfusion Reaction | 1 | 2023 | 7 | 0.220 |
Why?
|
One Health | 1 | 2023 | 1 | 0.220 |
Why?
|
Patient Preference | 1 | 2023 | 33 | 0.210 |
Why?
|
Social Determinants of Health | 1 | 2023 | 32 | 0.210 |
Why?
|
Middle Aged | 8 | 2022 | 9316 | 0.210 |
Why?
|
Glucocorticoids | 2 | 2020 | 70 | 0.210 |
Why?
|
Health Status Disparities | 1 | 2023 | 74 | 0.200 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 3 | 0.200 |
Why?
|
Adaptive Immunity | 1 | 2022 | 18 | 0.200 |
Why?
|
Vaccination | 1 | 2022 | 31 | 0.190 |
Why?
|
Delivery of Health Care | 2 | 2020 | 153 | 0.190 |
Why?
|
Antibodies, Viral | 1 | 2022 | 53 | 0.190 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 53 | 0.190 |
Why?
|
Anaphylaxis | 1 | 2021 | 11 | 0.190 |
Why?
|
Endpoint Determination | 1 | 2021 | 22 | 0.180 |
Why?
|
Biomedical Technology | 1 | 2021 | 8 | 0.180 |
Why?
|
Treatment Outcome | 7 | 2022 | 3620 | 0.180 |
Why?
|
Cross-Sectional Studies | 6 | 2021 | 935 | 0.180 |
Why?
|
Practice Patterns, Physicians' | 2 | 2019 | 122 | 0.180 |
Why?
|
Feedback | 1 | 2020 | 33 | 0.180 |
Why?
|
Remote Sensing Technology | 1 | 2020 | 3 | 0.180 |
Why?
|
Comparative Effectiveness Research | 2 | 2021 | 6 | 0.180 |
Why?
|
Clinical Coding | 1 | 2020 | 5 | 0.180 |
Why?
|
Confidentiality | 1 | 2020 | 7 | 0.180 |
Why?
|
Mental Health | 2 | 2020 | 122 | 0.180 |
Why?
|
Self-Management | 2 | 2017 | 14 | 0.180 |
Why?
|
Tiotropium Bromide | 1 | 2020 | 2 | 0.170 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2020 | 4 | 0.170 |
Why?
|
Desensitization, Immunologic | 1 | 2020 | 4 | 0.170 |
Why?
|
Self Report | 1 | 2021 | 226 | 0.170 |
Why?
|
Depression | 3 | 2020 | 454 | 0.170 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 239 | 0.170 |
Why?
|
Lung | 1 | 2021 | 170 | 0.170 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 40 | 0.170 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 25 | 0.170 |
Why?
|
Symptom Flare Up | 1 | 2019 | 2 | 0.170 |
Why?
|
Health Care Costs | 1 | 2020 | 80 | 0.160 |
Why?
|
Family Relations | 1 | 2019 | 14 | 0.160 |
Why?
|
Double-Blind Method | 3 | 2023 | 433 | 0.160 |
Why?
|
Societies, Medical | 1 | 2020 | 154 | 0.160 |
Why?
|
Residence Characteristics | 2 | 2019 | 214 | 0.160 |
Why?
|
Office Visits | 1 | 2019 | 13 | 0.160 |
Why?
|
Infection Control | 1 | 2020 | 166 | 0.160 |
Why?
|
Documentation | 1 | 2019 | 29 | 0.160 |
Why?
|
Pediatrics | 1 | 2019 | 46 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 81 | 0.150 |
Why?
|
Outpatients | 3 | 2023 | 59 | 0.150 |
Why?
|
Occupational Exposure | 1 | 2018 | 17 | 0.150 |
Why?
|
Patient Participation | 1 | 2018 | 53 | 0.150 |
Why?
|
Prevalence | 2 | 2018 | 467 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2023 | 329 | 0.140 |
Why?
|
Volunteers | 1 | 2017 | 5 | 0.140 |
Why?
|
Community Participation | 1 | 2017 | 18 | 0.140 |
Why?
|
Precision Medicine | 1 | 2017 | 29 | 0.140 |
Why?
|
Education, Distance | 1 | 2017 | 18 | 0.140 |
Why?
|
Cell Phone | 1 | 2017 | 7 | 0.140 |
Why?
|
Risk Factors | 4 | 2021 | 2412 | 0.140 |
Why?
|
Patient Transfer | 1 | 2016 | 23 | 0.140 |
Why?
|
Community Mental Health Services | 1 | 2015 | 19 | 0.130 |
Why?
|
Smartphone | 1 | 2015 | 17 | 0.120 |
Why?
|
Health Status | 3 | 2021 | 226 | 0.120 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 507 | 0.120 |
Why?
|
Retrospective Studies | 2 | 2022 | 3612 | 0.110 |
Why?
|
Peer Group | 1 | 2013 | 40 | 0.110 |
Why?
|
Housing | 1 | 2013 | 19 | 0.110 |
Why?
|
Risk Assessment | 3 | 2021 | 677 | 0.100 |
Why?
|
Drug Therapy, Combination | 3 | 2020 | 184 | 0.100 |
Why?
|
Animals | 2 | 2023 | 3812 | 0.100 |
Why?
|
Quality of Life | 3 | 2023 | 659 | 0.100 |
Why?
|
Obesity | 2 | 2019 | 321 | 0.100 |
Why?
|
Vagus Nerve Stimulation | 1 | 2012 | 8 | 0.100 |
Why?
|
Young Adult | 4 | 2022 | 2102 | 0.100 |
Why?
|
Chronic Disease | 1 | 2013 | 442 | 0.100 |
Why?
|
Pilot Projects | 2 | 2017 | 440 | 0.100 |
Why?
|
Aged | 3 | 2022 | 9334 | 0.100 |
Why?
|
School Health Services | 1 | 2011 | 21 | 0.090 |
Why?
|
Social Class | 1 | 2011 | 66 | 0.090 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 146 | 0.090 |
Why?
|
Age Factors | 1 | 2013 | 788 | 0.090 |
Why?
|
Students | 1 | 2011 | 53 | 0.090 |
Why?
|
Mexican Americans | 1 | 2011 | 29 | 0.090 |
Why?
|
Consensus | 2 | 2021 | 98 | 0.090 |
Why?
|
Ambulatory Care | 2 | 2022 | 74 | 0.090 |
Why?
|
Anti-Allergic Agents | 1 | 2010 | 2 | 0.090 |
Why?
|
Androstadienes | 1 | 2010 | 7 | 0.090 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2010 | 5 | 0.090 |
Why?
|
Quinolines | 1 | 2010 | 8 | 0.090 |
Why?
|
Acetates | 1 | 2010 | 17 | 0.080 |
Why?
|
Puerto Rico | 3 | 2014 | 13 | 0.080 |
Why?
|
Anxiety | 2 | 2021 | 161 | 0.080 |
Why?
|
Allergens | 2 | 2023 | 16 | 0.080 |
Why?
|
Respiratory Function Tests | 1 | 2009 | 36 | 0.080 |
Why?
|
Disease Progression | 2 | 2022 | 722 | 0.080 |
Why?
|
Logistic Models | 2 | 2019 | 396 | 0.070 |
Why?
|
Music | 1 | 2008 | 24 | 0.070 |
Why?
|
Drug Combinations | 2 | 2021 | 36 | 0.070 |
Why?
|
Emigration and Immigration | 1 | 2006 | 15 | 0.070 |
Why?
|
Forced Expiratory Volume | 2 | 2019 | 11 | 0.070 |
Why?
|
Interleukin-8 | 1 | 2023 | 19 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2023 | 12 | 0.050 |
Why?
|
Antibodies | 1 | 2023 | 49 | 0.050 |
Why?
|
Irritants | 1 | 2023 | 1 | 0.050 |
Why?
|
Prospective Studies | 2 | 2023 | 1807 | 0.050 |
Why?
|
Community-Based Participatory Research | 2 | 2014 | 43 | 0.050 |
Why?
|
Syndrome | 1 | 2023 | 82 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 72 | 0.050 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2023 | 3 | 0.050 |
Why?
|
Dry Powder Inhalers | 1 | 2022 | 3 | 0.050 |
Why?
|
Metered Dose Inhalers | 1 | 2022 | 5 | 0.050 |
Why?
|
Patients | 1 | 2022 | 35 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2022 | 43 | 0.050 |
Why?
|
Cytokines | 1 | 2023 | 231 | 0.050 |
Why?
|
Inflammation | 1 | 2023 | 288 | 0.050 |
Why?
|
RNA, Viral | 1 | 2021 | 45 | 0.050 |
Why?
|
Stakeholder Participation | 1 | 2021 | 10 | 0.050 |
Why?
|
Population Surveillance | 1 | 2022 | 110 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2021 | 12 | 0.050 |
Why?
|
Delphi Technique | 1 | 2021 | 27 | 0.050 |
Why?
|
Substance-Related Disorders | 2 | 2020 | 97 | 0.040 |
Why?
|
Qualitative Research | 1 | 2021 | 126 | 0.040 |
Why?
|
London | 1 | 2020 | 2 | 0.040 |
Why?
|
Terbutaline | 1 | 2020 | 1 | 0.040 |
Why?
|
United Kingdom | 1 | 2020 | 51 | 0.040 |
Why?
|
Self Administration | 1 | 2020 | 22 | 0.040 |
Why?
|
Professionalism | 1 | 2020 | 4 | 0.040 |
Why?
|
Health Care Rationing | 1 | 2020 | 6 | 0.040 |
Why?
|
Markov Chains | 1 | 2020 | 32 | 0.040 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2020 | 8 | 0.040 |
Why?
|
Guilt | 1 | 2020 | 5 | 0.040 |
Why?
|
Efficiency | 1 | 2020 | 20 | 0.040 |
Why?
|
Suicide | 1 | 2020 | 15 | 0.040 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 21 | 0.040 |
Why?
|
Grief | 1 | 2020 | 19 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 134 | 0.040 |
Why?
|
Community Health Services | 1 | 2020 | 35 | 0.040 |
Why?
|
Social Behavior | 1 | 2020 | 72 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 352 | 0.040 |
Why?
|
Mindfulness | 1 | 2020 | 48 | 0.040 |
Why?
|
Spirituality | 1 | 2020 | 80 | 0.040 |
Why?
|
Administration, Oral | 1 | 2019 | 111 | 0.040 |
Why?
|
ROC Curve | 1 | 2019 | 144 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2020 | 85 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 352 | 0.040 |
Why?
|
Social Media | 1 | 2020 | 50 | 0.040 |
Why?
|
Communication | 1 | 2020 | 124 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2019 | 66 | 0.040 |
Why?
|
Curriculum | 1 | 2020 | 164 | 0.040 |
Why?
|
Health Promotion | 1 | 2020 | 162 | 0.040 |
Why?
|
Smoking | 1 | 2019 | 176 | 0.040 |
Why?
|
Odds Ratio | 1 | 2019 | 268 | 0.040 |
Why?
|
Educational Status | 1 | 2019 | 298 | 0.040 |
Why?
|
Persuasive Communication | 1 | 2017 | 1 | 0.030 |
Why?
|
Focus Groups | 1 | 2017 | 93 | 0.030 |
Why?
|
Comorbidity | 1 | 2019 | 501 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2022 | 1863 | 0.030 |
Why?
|
Sinusitis | 1 | 2019 | 161 | 0.030 |
Why?
|
Patient Outcome Assessment | 1 | 2016 | 41 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2016 | 85 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2015 | 139 | 0.030 |
Why?
|
Primary Health Care | 1 | 2016 | 98 | 0.030 |
Why?
|
Schools | 1 | 2014 | 46 | 0.030 |
Why?
|
Cotinine | 1 | 2013 | 5 | 0.030 |
Why?
|
Tobacco Smoke Pollution | 1 | 2013 | 7 | 0.030 |
Why?
|
Enkephalin, Methionine | 1 | 1993 | 1 | 0.030 |
Why?
|
Saliva | 1 | 2013 | 60 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 1993 | 49 | 0.030 |
Why?
|
Vital Signs | 1 | 2012 | 3 | 0.020 |
Why?
|
Work of Breathing | 1 | 2012 | 6 | 0.020 |
Why?
|
Spirometry | 1 | 2012 | 12 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2012 | 233 | 0.020 |
Why?
|
Acute Disease | 1 | 2012 | 208 | 0.020 |
Why?
|
Program Evaluation | 1 | 2011 | 137 | 0.020 |
Why?
|
Fluticasone-Salmeterol Drug Combination | 1 | 2010 | 1 | 0.020 |
Why?
|
Sulfides | 1 | 2010 | 11 | 0.020 |
Why?
|
Cyclopropanes | 1 | 2010 | 15 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2012 | 244 | 0.020 |
Why?
|
Administration, Intranasal | 1 | 2010 | 27 | 0.020 |
Why?
|
Illinois | 1 | 2009 | 247 | 0.020 |
Why?
|
Body Mass Index | 1 | 2009 | 465 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2005 | 519 | 0.010 |
Why?
|
Vietnam | 1 | 1993 | 7 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1993 | 176 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1993 | 276 | 0.010 |
Why?
|
Alcoholism | 1 | 1993 | 74 | 0.010 |
Why?
|
Veterans | 1 | 1993 | 97 | 0.010 |
Why?
|